12:00 AM
 | 
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xarelto rivaroxaban regulatory update

The U.K.'s NICE said it needs additional information before it can recommend the use of Xarelto rivaroxaban from Bayer to prevent stroke and systemic embolism in patients with atrial fibrillation (AF). NICE said the population included in the Phase III ROCKET-AF trial of Xarelto was not reflective of all AF patients in the U.K. because the trial's mean time in therapeutic range...

Read the full 289 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >